Rishi P. Singh, MD
Show Description +
Rishi P. Singh, MD, reviews 52-week data from the PANORMA study, which assessed response to therapy in patients with nonproliferative diabetic retinopathy without diabetic macular edema who were treated with aflibercept. Patients were treated every 8 or 16 weeks with aflibercept or sham and were evaluated for 2-step improvements in retinopathy scoring.
Posted: 9/13/2019
Rishi P. Singh, MD
Rishi P. Singh, MD, reviews 52-week data from the PANORMA study, which assessed response to therapy in patients with nonproliferative diabetic retinopathy without diabetic macular edema who were treated with aflibercept. Patients were treated every 8 or 16 weeks with aflibercept or sham and were evaluated for 2-step improvements in retinopathy scoring.
Posted: 9/13/2019
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2019.
Please log in to leave a comment.